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Purpose: D9-Tetrahydrocannabinol-valine-hemisuccinate, a hydrophilic prodrug of
D9-tetrahydrocannabinol, synthesized with the aim of improving the ocular
bioavailability of the parent molecule, was investigated in a lipid-based nanoparticle
dosage form for ocular delivery.
Methods: Solid lipid nanoparticles (SLNs) of D9-tetrahydrocannabinol-valine-hemi-
succinate and D9-tetrahydrocannabinol, along with a nanoemulsion of D9-tetrahy-
drocannabinol-valine-hemisuccinate, were tested for glaucoma management in a
normotensive rabbit model by using a multiple-dosing protocol. Marketed
formulations of timolol maleate and pilocarpine HCl were also tested for their
pharmacodynamic profile, post-single dose administration.
Results: A peak intraocular pressure (IOP) drop of 30% from baseline was observed in
rabbits treated with SLNs loaded with D9-tetrahydrocannabinol-valine-hemisuccinate
at 90 minutes. Treated eyes of rabbits receiving D9-tetrahydrocannabinol-valine-
hemisuccinate SLNs had significantly lower IOP than untreated eyes until 360 minutes,
whereas the group receiving the emulsion formulation showed a drop in IOP until 90
minutes only. In comparison to marketed pilocarpine and timolol maleate ophthalmic
solutions, D9-tetrahydrocannabinol-valine-hemisuccinate SLNs produced a greater
effect on IOP in terms of both intensity and duration. In terms of tissue
concentrations, significantly higher concentrations of D9-tetrahydrocannabinol-
valine-hemisuccinate were observed in iris-ciliary bodies and retina-choroid with SLNs.
Conclusion: D9-Tetrahydrocannabinol-valine-hemisuccinate formulated in a lipid-
based nanoparticulate carrier shows promise in glaucoma pharmacotherapy.
Translational Relevance: Glaucoma therapies usually focus on decreased aqueous
humor production and increased outflow. However, such therapy is not curative, and
there lies a need in preclinical research to focus efforts on agents that not only affect
the aqueous humor dynamics but also provide neuroprotection. Historically, there
have been bench-scale studies looking at retinal ganglion cell death post-axonal
injury. However, for a smooth translation of this in vitro activity to the clinic, animal
models examining IOP reduction, i.e., connecting the neuroprotective activity to a
measurable outcome in glaucoma management (IOP), need to be investigated. This
study investigated the IOP reduction efficacy of cannabinoids for glaucoma
pharmacotherapy in a normotensive rabbit model, bringing forth a new class of
agents with the potential of IOP reduction and improved permeation to the back of
the eye, possibly providing neuroprotective benefits in glaucoma management.
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Introduction
Glaucoma is a neurodegenerative disorder charac-
terized by progressive peripheral vision loss due to
structural and functional damage to the optic nerve
head.1,2 The latest statistics from the World Health
Organization rank glaucoma as the second leading
cause of blindness, after cataracts, affecting almost 60
million people worldwide.3 The 2010 report by the
National Eye Institute stated that 2.72 million people
in United States suffer from glaucoma, which is 23%
higher than the 2.22 million affected in the year 2000,
and projects almost 6.3 million to be affected by this
illness by 2050.3–6
Glaucomatous optic neuropathy is caused by
several factors that result in the death of retinal
ganglion cells (RGCs) and their axons. The major risk
factor for glaucoma is elevated intraocular pressure
(IOP), normally regulated by aqueous humor (AH)
hydrodynamics in the anterior chamber.7 AH is a
fluid secreted by the iris-ciliary bodies (IC).8 AH
drains out via the trabecular meshwork (TM) through
the canal of Schlemm into venous circulation. The
ciliary muscles maintain the tension on the TM
structure and control the drainage of AH. The
Goldmann equation can be used to describe AH
hydrodynamics,9




where, Pe is the episcleral venous pressure (the
pressure opposing the drainage of AH through the
TM), F is the AH flow, U is the uveoscleral outflow,
and Ctrab is the AH outflow from the TM and
Schlemm canal.7 The balance between AH production
and drainage determines IOP, wherein increased AH
production or inadequate AH drainage might result
in increased pressure.7,10–12 Glaucoma medications
target IOP reduction by acting on the aforementioned
factors, i.e., either decreasing the production of AH
or increasing AH outflow through TM and through
the uveoscleral pathway or both.13–15
Currently, there are five families of treatment
governing the market as antiglaucoma agents,16
including adrenergic agonists, beta blockers, prosta-
glandin F2-a analogs, carbonic anhydrase inhibitors,
and cholinergic agents. The mechanism of action of
each class and examples of some Food and Drug
Administration-approved agents are listed in Table 1.
Current glaucoma research is directed toward finding
new lines of treatment, pursuing novel mechanisms
for lowering of the IOP. The recent Food and Drug
Administration approvals on antiglaucoma agents
Rhopressa (0.02% netarsudil), a rho-kinase inhibitor,
and Vyzulta (0.024% latanoprostene bunod, made of
two components, namely, latanoprost and a nitrogen
oxide-donating component), are examples of drug
products harnessing novel mechanisms of action for
IOP reduction.17 There are several investigational
treatments such as a sustained release bimatoprost
implant and ocular punctal plugs of travoprost and
latanoprost; however, all these approaches focus on a
formulation-based approach.17 A completely new
class of agents would bring forth another perspective
for antiglaucoma medications.
Cannabinoids have been investigated for the past
few decades for their IOP-lowering capacity. Canna-
binoids utilize several unique mechanisms for IOP
reduction. There are reports suggesting that IOP
reduction occurs due to decreased AH production, a
result of curtailed release of noradrenaline in ocular
tissues.18 D9-Tetrahydrocannabinol (THC) (Fig. 1) is
an example of a cannabinoid that favors the opening
of the endothelial-lined Schlemm’s channels draining
the AH.18–23 Another suggested mechanism involves
the CB1 receptors in IOP reduction. Human ciliary
bodies are rich in CB1 mRNA and functional protein,
supporting the hypothesis that cannabinoids such as
Figure 1. Chemical structures of (A) D9-tetrahydrocannabinol and
(B) D9-tetrahydrocannabinol valine hemisuccinate (THC-VHS).
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THC, through their action on CB1 receptors, may act
directly as vasodilators of the efferent blood vessels of
the anterior uvea, favoring AH efflux.24,25 Consider-
ing the pathophysiology of glaucoma, along with
increased IOP, there is also a neurodegenerative
component to the disease. Increased IOP produces
early injury in glaucomatous optic atrophy, resulting
in structural changes in the lamina cribrosa, a
membrane through which the RGC axons pass before
condensing to form the optic nerve.26–28 Moreover,
the overproduction of free radicals, such as nitric
oxide, results in an excessive release of glutamate,
which, by activating N-methyl-D-aspartate receptors,
results in apoptotic ganglionic cell death.29–31 Find-
ings suggest that THC can inhibit glutamic acid
release by increasing Kþ and decreasing Ca2þ perme-
ability.30,32,33 It also exhibits antioxidant properties
and prevents neuronal cell death by reactive oxygen
species scavenging action.22,34 Reportedly, in an
animal glaucoma model, treatment with THC for 20
weeks decreased IOP and reduced death of RGCs by
approximately 75%.35 This effect of THC on the RGC
provides the molecule with an added advantage of not
only IOP reduction but also neuroprotection.22,36
Hepler and Frank37 reported about a 25% to 30%
drop in IOP after smoking marijuana, in a small
number of subjects with a duration of action of 3 to 4
hours.38 Crawford and Merritt39 in the late 1970s
conducted clinical studies to determine a relationship
between changes in heart rate, blood pressure, IOP in
normotensive (n¼ 8) and hypertensive volunteers (n¼
8), and also patients diagnosed with open-angle
glaucoma (n¼ 16), and they observed decreased IOP
(6–21 mm of Hg lower than control) along with
intense cardiovascular effects. Overall, it has been
observed that smoking marijuana is accompanied
with a drop in both systolic pressure as well as IOP;
however, cardiovascular effects, such as tachycardia
and postural hypotension, outweigh the IOP-lowering
effects, giving rise to the need of investigating the
effect of topical application of THC on lowering
IOP.38,39 A number of studies examined the topical
administration of THC formulated in various oily
vehicles.40–43 However, for THC to show both an
IOP-reducing and a neuroprotective effect, it is
important for it to permeate through the outer layers
of the eye to target tissues in the anterior and
posterior compartments.24,44 Previously, a prodrug
approach was devised aiming to improve the ocular
bioavailability of THC.45,46 Adelli et al.4 evaluated
the pharmacokinetic and pharmacodynamic (PK-PD)
efficacy of a hydrophilic prodrug of THC, D9-THC-
valine-hemisuccinate (THC-VHS) (Fig. 1) in an
elevated IOP model. THC-VHS demonstrated a
better permeation profile in comparison to THC,
penetrating to the IC and retina choroid (RC), and
Table 1. Classification and Mechanisms of Action of the Currently Used Antiglaucoma Medications
Antiglaucoma Medications Mechanism of Action FDA-Approved Therapy
Prostaglandin analogs Reduction in hydraulic resistance
to uveoscleral outflow, increase




Beta blockers Reduce aqueous humor
production by acting on the b1
and b2 receptors

















Cholinergic agents Increases aqueous humor outflow
by contracting longitudinal




FDA, Food and Drug Administration.
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displayed a corresponding IOP drop for about 180
minutes.47
To understand the IOP-lowering mechanisms of
THC-VHS in an intact eye with all the production
and drainage mechanisms unimpaired, a normoten-
sive IOP model was opted for in the current set of
studies. The goals of this project were to formulate a
lipid-based vehicle, solid lipid nanoparticles (SLNs),
to improve the delivery of the prodrug THC-VHS to
the target tissues. SLNs have been reported to
enhance ocular bioavailability by prolonging the
residence time of the formulation in the cul de sac,
forming a lipid-based drug reservoir interacting with
the ocular mucosa.48
The formulation was characterized in terms of
drug content (% w/v), particle size (d.nm), polydis-
persity index (PDI), and scanning transmission
electron microscopy (STEM). The stability of the
formulations in terms of particle size growth under
different storage conditions was investigated. A
comparative PK-PD profile of the THC-VHS-SLN
formulations was established after single and multiple
topical applications in a normotensive rabbit model.
The PK-PD profile of THC-VHS-SLN was compared
to that of THC-VHS formulated in a soybean oil-
based emulsion and THC-SLN to delineate the effect
of prodrug derivatization and the effect of vehicle in
improving ocular bioavailability. IOP-lowering effi-
cacy (PD profile) of the formulations was also
compared against marketed ophthalmic formulations
of pilocarpine and timolol maleate in the same model
(single dose).
Materials
THC-VHS was synthesized by ElSohly Laborato-
ries, Inc., according to previously established proto-
cols.49 Compritol 888 ATO (glyceryl behenate) was
obtained as a gift sample from Gattefossé (Paramus,
NJ), glycerin was purchased from Acros Organics
(NJ), Pluronic F68 (poloxamer 188) was purchased
from Spectrum Pharmaceuticals (Henderson, NV),
Tween 80 was received as a gift sample from Croda,
Inc., (Mill Hall, PA), and Tocrisolve 100 was
purchased from Tocris Biosciences (Bristol, UK).
High-performance liquid chromatography (HPLC)-
grade solvents and other chemicals (analytical grade)
were obtained from Fisher Scientific (Hampton, NH).
Amicon Ultra centrifugal filter devices, namely,
regenerated cellulose membranes (MWCO 100 kDa),
were purchased from EMD Millipore (Billerica, MA).
Formalin was purchased from Thermo Scientific
(Waltham, MA). Timolol maleate eye drops (0.25%
w/v) and pilocarpine HCl eye drops (2% w/v) are
commercially available formulations obtained from
The University of Mississippi Health Center.
Animals
Male New Zealand White (NZW) rabbits (2–2.5
kg), obtained from Harlan Laboratories (Indianapo-
lis, IN), were used in all studies. All animal
experiments conformed to the Association for Re-
search in Vision and Ophthalmology statement ‘‘Use
of Animals in Ophthalmic and Vision Research’’ and
followed the University of Mississippi Institutional
Animal Care and Use Committee approved protocols.
Development of SLNs and Emulsion
THC-VHS-SLNs and THC-SLNs
THC-VHS- or THC-loaded SLNs were prepared
by the ultra-sonication technique. Compritol 888
ATO constituted the lipid phase of the SLNs. THC-
VHS (equivalent to 0.6% w/v of THC) and 0.6% w/v
of THC was mixed with Compritol 888 ATO to
obtain a clear lipid phase. The aqueous phase
comprising of Pluronic F-68 (0.25% w/v), Tween 80
(0.75% w/v), and glycerin (2.25% w/v) was simulta-
neously heated in bidistilled water. The hot aqueous
phase was added to the melted lipid phase under
constant stirring. A coarse emulsion from this premix
was formed by emulsification at 11,000 rpm for 5
minutes by using a T 25 digital Ultra-Turrax
instrument. This coarse emulsion was subjected to
ultrasonification using SONICS Vibra-Cell Ultrason-
ic Liquid Processor by using previously optimized
parameters (amplitude: 40%; pulse on: 10 seconds,
pulse off: 15 seconds; time: 10 minutes). The
temperature during this entire process was maintained
at 708C. The hot emulsion was slowly cooled to room
temperature to form THC-VHS or THC SLNs.
THC-VHS and THC Emulsion
THC-VHS and THC emulsion were prepared by
dispersing a weighed amount of THC (0.6% w/v) or
THC-VHS (0.98% w/v, equivalent to 0.6% w/v THC)
in the Tocrisolve emulsion vehicle (THC-TOC and
THC-VHS-TOC), a soya-bean oil emulsion composed
of a 1:4 ratio of soya oil/water, purchased from Tocris
Bioscience. Tocrisolve is a water-soluble emulsion
used for formulating hydrophobic moieties such as
cannabinoids. The soybean oil solubilizes the canna-
binoid molecule, and the emulsion is stabilized by the
block copolymer Pluronic-F68, preventing the lipid
droplets from coalescing in the dispersion. This
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mixture was vortexed for 5 minutes on Ultra Cylone
and sonicated for 10 minutes.
Formulation Characterization
Drug Content
To determine the drug content in the SLNs and the
emulsion, the lipid/oil was precipitated using ethanol.
An accurately measured volume of the formulation
was extracted in 1 mL ethanol, and this suspension
was centrifuged at 13,000 rpm for 15 minutes. The
drug content in the supernatant was analyzed using
the following HPLC-ultraviolet method.
In Vitro Sample Analysis
The samples were analyzed for THC and THC-
VHS by using an HPLC-ultraviolet system compris-
ing a Waters 717 plus Autosampler, Waters 600E
pump controller, Waters 2487 dual k absorbance
detector, and an Agilent 3395 integrator. Stock
solutions of THC-VHS and THC were prepared in
acetonitrile and used immediately. A mobile phase
consisting of 60:40 (acetonitrile:water) with 0.1%
glacial acetic acid was used on a Phenomenex C18
(4.6 3 250 mm) column at a flow rate of 1 mL/min.
Detection was carried out at 226 nm.
Particle Size and PDI
The mean particle size and the PDI of the THC-
VHS-SLN, THC-SLN, and THC-VHS-TOC formu-
lations were determined by the Dynamic Light
Scattering technique using the Zetasizer Nano ZS
Zen3600 (Malvern Instruments, Inc., Malvern, UK)
at 258C and 1738 detection optics by using the Non-
Invasive-Back-Scatter technology. The cells used were
disposable folded capillary clear cells. The measure-
ments were obtained using a helium-neon laser of
633nm, and the particle-size analysis data were
evaluated using intensity distributions. To measure
the particle size distribution, the samples were diluted
(1:500) with bidistilled water filtered using 0.2-micron
filters.
STEM Studies
A negative staining procedure was used to conduct
the STEM studies. THC-VHS-SLNs were character-
ized by a scanning transmission electron microscope
Zeiss Auriga-40 dual beam by using 1% w/v uranyl
acetate as a stain. Twenty microliters of the sample
was placed on a piece of parafilm, and a glow
discharged 200 mesh copper grid with a thin carbon
film was floated on the top of the sample (film side
down) for 30 seconds. After taking the grid off the
drop, the excess sample was blotted using a piece of
filter paper. The grid was then floated on a drop of
distilled water for a couple of seconds. Once the
excess water was removed, the grid, sample side
down, was floated on a drop of 1% uranyl acetate for
1 minute. After blotting and drying, the samples were
imaged in a Zeiss Libra operating at 30 kV and in
STEM mode.
Physical and Chemical Stability
THC-VHS-SLNs were evaluated for changes in %
drug content, particle size, and PDI on storage at
conditions of 408C/60% relative humidity (RH), 258C/
75% RH, and 48C.
Corneal Histology
Six NZW rabbits were used for comparison of
corneal histology after treatment with placebo-SLNs
or with isotonic phosphate buffer saline (IPBS) as the
control (n ¼ 3). The placebo-SLNs were topically
administered to the eye of normotensive NZW rabbits
to observe the effect of the vehicle on the histological
characteristics of the cornea. Rabbit corneas dosed
with IPBS, under similar experimental conditions,
were used as controls. The study was conducted for
120 minutes, after which the animals were euthanized,
and the corneas were excised. Extracted corneas were
fixed in 10% neutral buffered Formalin. Histological
evaluation was carried out at Excalibur Pathology
Inc. (Oklahoma City, OK) as per previously reported
protocols. Corneas embedded in paraffin were sliced
into 5-lm cross sections by using a microtome
(American Optical 820 Rotary Microtome). These
sections were placed on a slide and dried overnight in
an oven at 688C. The slide was washed with xylene to
remove paraffin and washed with alcohol and water
to hydrate the tissue. This was then stained with
nuclear dye Gill III hematoxylin (StatLab Medical,
McKinney, TX) for 10 min and rinsed and then
counterstained with eosin. These slides were then
washed in reverse manner (running water, alcohol,
and xylene), cover slipped, and examined under a
microscope (Chroma Vision ACIS II).
Efficacy Studies
Multiple-Dose Studies
The rabbits were acclimatized to the environment,
personnel, and IOP measurements by using a Tono-
Pen Vet (Reichert Technologies, Depew, NY) for a
period of 2 to 3 weeks. The formulations THC-VHS-
SLNs, THC-VHS-TOC, and THC-SLNs were dosed
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topically, conforming to a predetermined multiple-
dosing protocol in 18 NZW rabbits (n ¼ 6). Fifty
microliters of SLNs or nanoemulsion (in Tocrisolve)
was instilled topically in the cul de sac of the left eye
of normotensive rabbits, twice a day, for 5 consecu-
tive days. The right eye served as the control. To
avoid spillage, the eyelid was closed for 10 seconds.
On day 1, for the single-dose IOP-time profiling, IOP
was measured before (baseline IOP), and every 30
minutes after administration until IOP returned to
90% of the baseline. From day 2 onward, the IOP was
measured before (baseline) and 60 to 90 minutes after
administration of the dose. The IOP value displayed
by the Tono-Pen Vet was an average of five
concurrent IOP measurements, and each time point
was measured in triplicate. The decrease in IOP was
recorded as a function of single dose and multiple
dosing, that is an intraday as well as an interday IOP
trend was monitored. On day 5, IOP-time profiling
was done similar to day 1. On day 6, the animals were
sacrificed at two time points: the first time point,
which showed the lowest drop in IOP on day 5, and
the second time point right before the IOP returned to
90% IOP from the baseline.
Eye Dissection and Tissue Collection
At the time points mentioned before, the rabbits
were administered ketamine (35 mg/kg) and xylazine
(3.5 mg/kg) intramuscularly and euthanized under
anesthesia with an overdose of pentobarbital admin-
istered through the marginal ear vein. The eyes were
immediately enucleated after washing with ice-cold
isotonic phosphate-buffered saline. Enucleated eye-
balls were then dissected and the AH, vitreous humor
(VH), IC, and RC tissues were collected. All samples
were weighed and stored at 808C until further
processing.
Bioanalytical Methods for Quantification
An AB Sciex QTrap 4500 (Framingham, MA)
liquid chromatography-tandem mass spectrometry
quadrupole interfaced with Shimadzu Nexera HPLC
(Kyoto, Japan) was used to analyze both the THC
and THC-VHS content. Calibration curves were
prepared by spiking THC and THC-VHS into blank
ocular tissues along with the internal standard D3-
THC. The tissues analyzed were AH, VH, IC, RC,
and plasma. Protein precipitation took place after the
addition of ice-cold acetonitrile, followed by extrac-
tion of THC and THC-VHS. The samples were
vortexed and then centrifuged at 13,000 rpm for 30
minutes. The supernatant was filtered through a 0.2-
lm filter, and the filtrate was analyzed for THC and
THC-VHS content. The calibration curves were
prepared with both THC and THC-VHS in AH
(2.5–100 ng/mL), VH (2.5–100 ng/mL), IC (2.5–100
ng/mL), RC (2.5–100 ng/mL), and plasma (2.5–100
ng/mL). Tissues collected from the multiple-dosing
studies were also prepared per this protocol. A
Phenomenex Synergi Hydro Reverse Phase, 100 A,
50 3 3-mm, 2.5-lm column was used with a gradient
elution method; the solvent phase was composed of
water and acetonitrile with 0.1% w/v formic acid.
Single-Dose Studies
Single-dose IOP-lowering efficacy studies were
conducted with the marketed ophthalmic formula-
tions of timolol maleate (0.25% w/v) and pilocarpine
HCl (2% w/v) in NZW rabbits (n ¼ 4). Fifty
microliters of each test formulation was instilled into
the lower cul de sac of the left eye of the rabbits, while
the right eye acted as the control. The eyelids were
closed after the instillation for 10 seconds to avoid
spillage. IOP was measured before instillation (base-
line IOP) and every 30 minutes postinstillation until
the IOP returned to 90% of baseline IOP. The drop in
IOP was also expressed as DIOP or percent baseline
IOP (6 SEM), that is (measured IOP/baseline IOP)3
100.
Statistical Analysis
To assess the effect of formulation on change in
IOP over time, a repeated measures model was used.
Between and within group differences were modeled
using the proc mixed procedure with treatment, time
and interaction of treatment and time as independent
factors in the model. A two-tailed P value of 0.05
was considered statistically significant. Data analysis
was conducted using Statistical Analysis System 9.4
software (SAS Institute, Cary, NC). A P value of less
than 0.05 was considered statistically significant.
Results
Formulation Characterization
A detailed description of the compositions of these
formulations has been listed in Table 2.
The homogenization-ultrasonication process yield-
ed SLNs with hydrodynamic radii less than 300 d.nm
and a narrow distribution range. However, their
particle size was slightly greater than that of
Tocrisolve emulsion. Tocris Bioscience reports the
mean droplet size of the emulsion as 182 nm, and our
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investigated values for THC-VHS-TOC particle size
fall along similar lines (189.75 6 22.7 d.nm). The
physicochemical properties of the test formulations
are listed in Table 3. A narrow PDI suggests no
aggregation/coalescence of the nanocolloidal formu-
lations.
STEM Studies
Morphological characteristics of THC-VHS-SLNs
were studied using STEM (Fig. 2). STEM technique
images samples based on absorption of an electron
beam as it passes through an ultra-thin layer of
sample. The transmitted beam is then projected on a
phosphorescent screen or detector, providing us with
information regarding the morphological characteris-
tics of the particles as well as the hydrodynamic
radius. The electron microscopy pictures at different
magnifications (Fig. 2) show the presence of spherical
nanoparticles with a smooth, well-defined periphery.
Physical and Chemical Stability
The particle size and PDI of THC-VHS-SLNs was
observed for 6 months at 408C/60% RH 258C/75%
RH, and 48C. The formulations were stable over a
period of 6 months at both 48C and 258C, with
particle size remaining around 200 to 300 d.nm and a
PDI of 0.3 (Fig. 3).50 However, after 1 month at 408C,
a 95% increase in particle size was observed from the
original diameter of 248.9 nm and a PDI of 0.4. In
terms of drug content, the THC-VHS-SLN was stable
with a change in drug content of 61.5% when stored
at 48C and 258C over a period of 23 days (the last
timepoint checked).
Corneal Histology
To observe the effect of formulation on the corneal
histology, cross sections of rabbit corneas treated with
placebo-SLNs (Figs. 4A, 4B, 4C) and IPBS (control)
were studied (Figs. 4D, 4E, 4F). The cornea is
composed of five membranes, namely, the corneal
stratified squamous epithelium (1), Bowman’s mem-
brane (2), stroma consisting of collagen fibers and
keratocytes (3), Descemet’s membrane (4), and the
endothelium (5), as marked in Figure 4A. The corneal
epithelium of all the rabbits treated with control or
placebo-SLNs looked intact and attached to the
Bowman’s membrane, without any signs of edema.
Efficacy Studies
Multiple-Dosing Regimen for THC-VHS-SLN
It has been previously reported that THC fails to
lower the IOP of normotensive rabbits. The data
obtained on normotensive rabbits for studies with
THC-VHS-SLN formulations show a significant IOP-
lowering effect by THC-VHS when formulated in
SLNs. Figure 5 depicts the 5-day mean IOP versus
time profile for a treated eye after dosing with THC-
VHS-SLN over the 5-day dosing regimen in compar-








Compritol 888 ATO 3 - 3
Glycerin 2.25 - 2.25
Poloxamer 188 0.25 - 0.25
THC - - 0.6
THC-VHS (0.6% THC equivalent) 0.98 0.98 -
Tocrisolve emulsion - Q.S -
Tween 80 0.75 - 0.75
Water, HPLC grade Q.S - Q.S
Q.S, quantum sufficit.
Table 3. Particle Size, PDI, and Drug Content of Test Formulations THC-VHS-SLN, THC-VHS-TOC, and THC-SLN
Formulation Particle Size, d.nm PDI Drug Content, % w/v
THC-VHS-SLN, mean 6 SD 287.80 6 7.35 0.29 6 0.01 93.57 6 4.68
THC-VHS-TOC, mean 6 SD 189.75 6 22.7 0.15 6 0.06 87.74 6 3.6
THC-SLN, mean 6 SD 269.2 6 5.66 0.32 6 0.15 96.84 6 0.02
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ison to the contralateral eye IOP (untreated eye). The
IOP of the treated eye was significantly lower than the
untreated eye from the 30-minute time point, and this
effect lasted until 360 minutes.
Multiple-Dosing Regimen for THC-VHS-TOC
The THC-VHS-TOC emulsion formulation did not
have a significant effect on the IOP of normotensive
rabbits. The 5-day mean IOP versus time profile for the
eye treated with THC-VHS-TOC in comparison to the
contralateral eye is shown in Figure 6. The IOP drop in
the treated eye lasts for about 90 minutes, with IOP
significantly lower than the contalateral eye at the 30-,
60-, and 90-minute time points.
Multiple-Dosing Regimen for THC-SLN
To elucidate the effect of prodrug derivatization,
the efficacy of the THC-SLN formulations was also
tested. The mean 5-day IOP versus time profile
comparing the THC-SLN treated and contralateral
eyes is shown in Figure 7. The eyes receiving THC-
SLNs did not show a significant drop in IOP in
comparison to the contralateral eye up to 90 minutes.
However, at the 135-minute time point, the IOP of the
treated eye was significantly lower than the contra-
lateral eye. After a period of 2.5 hours, at the 285
minute time point, this effect was reversed and the
contralateral eye showed significantly lower IOP in
comparison to the treated eye.
Figure 8 illustrates statistically significant within-
group differences, comparing IOP for the same
treatment with baseline IOP (time point 0) and
between-group differences for different formulations
at various time points. Looking at the within-group
differences for treatment THC-VHS-SLNs, the drop
in IOP at time points 60, 90, 120, and 180 minutes is
significantly lower than baseline IOP (time point, 0
minutes), with P values of 0.011, ,0.0001, ,0.0001,
and 0.0021, respectively. A proc mixed repeated
measures model was used with a Tukey Kramer
adjustment to assess these differences. Other treat-
ment formulations, THC-VHS-TOC, and THC-SLNs
do not show significantly lower IOP in comparison to
baseline IOP. Analyzing between-group differences,
THC-VHS-SLNs demonstrated significantly lower
IOP than THC-SLNs (P , 0.0001) and THC-VHS-
TOC (P ¼ 0.0019) at time points 60, 90, and 90
minutes, respectively.
Ocular Bioavailability
For THC-VHS-SLN, the maximum drop in the
IOP from the baseline (DIOPmax) was 31% and
29.3% on day 1 and day 5, respectively. The time to
achieve DIOPmax (Tmax) on day 1 and day 5, was 90
minutes, and the duration of action for THC-VHS-
SLN, or the time required for DIOP to reach 90% of
baseline IOP, was 480 minutes on both days 1 and 5.
The two sacrificial time points, determined based on
the IOP data, were 90 and 360 minutes. Table 4
displays the concentration of both THC-VHS and
the parent molecule at the two sacrificial time points.
At 90 minutes, THC-VHS concentrations were 10.67
6 2.28 ng/50 mg in AH and decreased to 3.84 6 0.53
ng/50 mg at 360 minutes. In comparison to AH,
higher levels of the prodrug were observed in the IC
and RC, with 1466 6 514.5 ng/50 mg and 902 6 372
ng/50 mg observed at 90 minutes and 77.6 6 69.5 ng/
50 mg and 238.3 6 143.3 ng/50 mg observed at the
360-minute time points, respectively. At 360 minutes,
6.36 6 3.83 ng/50 mg of bioreversed THC was
Figure 2. STEM images of THC-VHS-SLN at (A) 92.29 KX and (B)
209.82 KX magnification.
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Figure 3. Particle size and polydispersity index of THC-VHS-SLNs stored at conditions of 408C/60% RH, 258C/75% RH, and 48C over a
period of 6 months.
Figure 4. Histological sections of rabbit corneas (magnification, 103) excised from NZW rabbits (n¼ 3) treated with placebo-SLNs (A, B,
C) and IPBS (control) (D, E, F) 120 minutes after application.
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observed in the IC. Significant amounts of drug
permeated to the RC and IC tissues, which are both
important from the point of view of neuroprotection
and IOP lowering, and a corresponding IOP drop
was observed as the pharmacodynamic response.
THC-VHS was not observed in the plasma even after
multiple administration, which helps rule out central
nervous system involvement through systemic expo-
sure.
For THC-VHS-TOC, the DIOPmax for day 1 and
day 5 of dosing was 11.7% and 10.9%, respectively,
and the Tmax was 60 minutes. Thus, the sacrifice time
points determined for this formulation were 60 and
120 minutes. The ocular concentrations of THC-VHS
obtained with the THC-VHS-TOC formulation were
significantly lower than those obtained with the THC-
VHS SLN formulation (Table 5).
Consistent with the previously reported data, THC
did not produce as intense or as prolonged an IOP
drop from baseline IOP in comparison to the THC-
VHS formulations.4 A 6.9% drop in IOP in compar-
ison to the baseline IOP was observed with THC-
SLNs at 60 minutes on day 5. Animals were sacrificed
at two time points on day 6 at 60 and 120 minutes
(Table 6). THC levels of 12.53 6 3.51 ng/50 mg and
9.87 6 3.22 ng/50 mg were observed in the IC at 60
and 120 minutes, respectively.
Single-Dose Efficacy Studies
Pilocarpine HCl (2% w/v) exhibited a DIOPmax of
15.9% at 30 minutes, and its IOP-lowering effect
lasted for 120 minutes (Fig. 9). The graphs represent
%IOP drop from the baseline IOP. Timolol maleate
(0.25% w/v) resulted in a more intense DIOPmax of
23.1% at 60 minutes, with a duration of action of 180
minutes for the IOP to reach 90% of the baseline IOP.
THC-TOC emulsion or the placebo-SLNs did not
result in any reduction in IOP (data not shown). The
IOP versus time profiles of the marketed preparations
are compared to that of the THC-VHS-SLNs, THC-
VHS-TOC, and THC-SLNs in Figure 9.
Figure 5. Mean IOP versus time profile for treated (dotted line) and untreated (solid line) eyes in normotensive rabbits (n¼6) dosed with
50 lL of 0.98% w/v THC-VHS-SLN twice a day for 5 consecutive days. The line represents the mean of these data points at each time point
(6 SEM). The IOP profiles of the treated were contralateral rabbit eyes were compared using a proc mixed repeated measures model. The
P values for treated versus untreated eyes are also listed.
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Discussion
In 1977, Green et al.51 reported a 17% drop in the
IOP, 60 minutes after dosing, by using THC formulated
in light mineral oil as the vehicle in adult albino rabbits.
The tissue concentrations obtained were extremely low,
namely, about 1 ng of 14C-labeled THC/mg of wet
tissue weighed 4 hours after dosing in the cornea and
IC. Hingorani et al.52 observed that the amount of
THC permeating into the ocular tissues was below
levels of detection in rabbit AH, VH, RC, and IC, 1
hour postadministration of THC in light mineral oil
(0.1% w/v), emulsion (0.37% w/v), or micellar solutions
(0.125% w/v THC, 0.5% w/v Cremophor RH 40) in
NZW rabbits, with detectable levels only in the cornea
and sclera. Such findings suggest that the lipophilic
nature of THC prevents its partitioning from the oily
vehicle into the tear film, in turn affecting its overall
ocular bioavailability. THC has poor aqueous solubility
(1–2 lg/mL) and high log P (6.42), which makes the
development of an eye drop for the molecule challeng-
ing. The lack of activity through the topical route of
application, as observed in the abovementioned reports,
could be due to the ineffective delivery of THC to the
target ocular tissues rather than the absence of local
pharmacological activity. The delivery of a therapeutic
agent to the deeper ocular tissues depends on the type
of formulation, physicochemical properties of the
molecule, and absorption pathway.53 These properties
determine the permeation profile of the molecule across
alternating lipophilic and hydrophilic tissue layers and
through the corneal tight junctions. For targeting a
molecule to the back of the eye, it should possess
optimum physicochemical properties and be formulat-
ed in appropriate dosage forms.54
Figure 6. Mean IOP versus time profile for treated (dotted line) and untreated (solid line) eyes in normotensive rabbits (n¼6) dosed with
50 lL of 0.98% w/v THC-VHS-TOC twice a day for 5 consecutive days. The lines represent the mean of these data points at each time
point (6 SEM). The IOP profile of the treated versus contralateral rabbit eyes were compared using proc mixed repeated measures model.
The P values for treated versus untreated eyes are listed in the figure.
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To improve the intrinsic solubility of THC, a
prodrug strategy was used by Hingorani et al.52,55 by
using a hemiglutarate (dicarboxylic acid) ester (THC-
HG), which, being ionized at physiological pH, would
have better aqueous solubility (19 lg/mL). One hour
postinstillation of 50 lL of THC-HG, formulated in
0.5% w/v Cremophor RH 40, 35.6 6 12.5 ng of THC/
50 mg of tissue was observed in the IC and 32.1 6 12.6
ng of THC/100 lL was detected in AH of NZW
rabbits, whereas the THC tissue concentrations ob-
tained postdosing of 50 lL THC formulated in 0.5% w/
v Cremophor RH 40 were below detection levels. This
finding suggested that hydrophilic prodrug derivatiza-
tion is an efficient method to improve the ocular
bioavailability of THC.52 However, in terms of
chemical stability, THC-HG was extremely unstable
and underwent rapid degradation at acidic and alkaline
pH conditions, as well as at physiological pH.55,56
In subsequent studies, THC-VHS was designed as
an amino acid-dicarboxylic acid prodrug, with the
amide linkage enhancing its stability. In terms of the
physicochemical properties, THC-VHS is stable from
pH 5 to pH 9.49 Adelli et al.4 observed the efficacy of
THC-VHS in a soybean oil-based emulsion in an
elevated IOP-glaucoma model. THC-VHS demon-
strated an IOP drop comparable to the marketed
ophthalmic solution of 2% (w/v) pilocarpine HCl.47
However, the IOP versus time profile indicated that
frequent dosing would be necessary. Thus, developing
a formulation strategy that could increase the amount
of THC-VHS that could enhance the bioavailability
as well as retention of the therapeutic agent at the
ocular surface would be desirable.
Posttopical application, a molecule has to over-
come significant barriers, such as vascular and
lymphatic drainage in the conjunctiva, sclera, and
Figure 7. Mean IOP versus time profile for treated (dotted line) and untreated (solid line) eyes in normotensive rabbits (n¼6) dosed with
50 lL of 0.6% w/v THC-SLNs twice a day for 5 consecutive days. The line represents the mean of these data points at each time point (6
SEM). The IOP profiles of the treated versus contralateral rabbit eyes were compared using a proc mixed repeated measures model. The P
values for treated versus untreated eyes are listed in the figure.
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choroid, restricting its passage from the ocular surface
to posterior ocular tissues.57 SLNs enhance the ocular
bioavailability of poorly soluble compounds by acting
as unit carriers of the target molecules and prolonging
its residence time in the cul de sac and forming a lipid-
based drug reservoir that interacts with the ocular
mucosa.48,54,58,59 SLNs, being solid at room temper-
ature, have a modulated drug release profile in
comparison to a liquid based-formulation.60 Punya-
murthula et al.48 demonstrated enhanced delivery of
D8 THC-SLNs to all ocular tissues attributed to the
probable uptake of the SLNs by the conjunctival and
corneal membranes, resulting in sustained release of
the drug.
However, to develop an SLN formulation of
THC-VHS, the thermal stability of the prodrug
would play an important role during formulation
development. Both molecules, THC and THC-VHS,
Figure 8. Comparative mean IOP versus time profiles for rabbits
treated with 50 lL of 0.98% THC-VHS-SLN, 0.98% w/v THC-VHS-
TOC, or 0.6% w/v THC-SLNs (n ¼ 6) twice a day for 5 consecutive
days. The line represents the mean of these data points at each
time point (6 SEM). The rabbit eyes receiving the different
formulations were compared using a proc mixed repeated
measures model.
Table 4. Tissue Concentrations of THC-VHS and THC
on Day 6 Postinstillation of 50 lL of 0.98% w/v THC-
VHS-SLNs, at 90 Minutes (n¼ 3) and 360 Minutes (n¼
3) in Aqueous Humor, Vitreous Humor, Retina Choroid,











Aqueous humor 90 10.7 6 2.3 ND
360 3.8 6 0.5 ND
Vitreous humor 90 ND ND
360 ND ND
Iris ciliary bodies 90 1466 6 514.5 ND
360 77.6 6 69.5 6.4 6 3.8
Retina choroid 90 902 6 372 ND
360 238.3 6 143.3 ND
ND, below limits of detection.
Table 5. Tissue Concentrations of THC-VHS and THC
on Day 6 Postadministration of 50 lL of 0.98% w/v
THC-VHS-TOC, at 60 Minutes (n ¼ 3) and 120 Minutes
(n ¼ 3) in Aqueous Humor, Vitreous Humor, Retina












Aqueous humor 60 91.2 6 1.85 ND
120 ND ND
Vitreous humor 60 ND ND
120 ND ND
Iris ciliary bodies 60 24.2 6 5.06 53 6 28.9
120 11.3 6 0.50 57.4 6 18.5
Retina choroid 60 15.5 6 6.70 5.2 6 0.2
120 7.5b 5.3b
ND, below limits of detection.
a Table has been reproduced with permission.4
b Drug levels observed in a single animal only.
Table 6. Tissue Concentrations of THC on Day 6
Postadministration of 50 lL of 0.98% w/v THC-SLN, at
60 Minutes (n¼3), and 120 Minutes (n¼3) in Aqueous
Humor, Vitreous Humor, Retina Choroid, and Iris Ciliary








Aqueous humor 60 ND
120 ND
Vitreous humor 60 ND
120 ND
Iris ciliary bodies 60 12.5 6 3.5
120 9.9 6 3.2
Retina choroid 60 ND
120 ND
ND, below limits of detection.
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are amorphous with the absence of a definite crystal
lattice structure, making them susceptible to atmo-
spheric degradation.56,61 THC undergoes rapid
thermo-oxidative degradation into its metabolite
cannabinol. The use of polymeric stabilizers and
cross-linked matrices can be considered as a way of
controlling the oxidative degradation of amorphous
molecules such as THC.61–63 Compritol 888 ATO is a
crystalline amphiphilic material with a melting point
of about 708C. The crystalline structure of the bulk
lipid can form protective barriers increasing the
storage stability of the formulation.64 The high
solubility of THC and THC-VHS in Compritol 888
ATO, along with the stabilizing effect provided by
the crystalline lipid, make it a good choice of lipid
for the development of the SLN formulation.
Previous reports show that THC-VHS shows only
about 3% degradation of drug when heated at 1208C
for 10 minutes.49 Taking into consideration this
along with the melting point of Compritol 888 ATO,
a temperature of 708C was chosen to formulate the
SLNs.
The physicochemical data suggest that a structured
lipid phase comprising of Compritol 888 ATO
(stabilized by a poloxamer 188-Tween 80 surfactant
system) resulted in a stable nanoparticulate system.
The data obtained from the STEM indicate that the
size of the well-rounded nanoparticles is slightly
greater than 200 nm, which is also consistent with
the results obtained from Dynamic Light Scattering.
In the case of multimodal data, particle size may not
agree across different measurement techniques; how-
ever, for a monodisperse formulation, the particle size
data might be comparable.65,66 At the 6-month time
point, complete gelation of the SLN formulation at
the storage condition of 408C/60% RH was observed
(Fig. 2). The temperature-dependent dynamics of an
emulsifier-stabilized colloidal system has been gov-
erned by an interplay of several variables. Increase in
the temperature at the storage condition of 408C/60%
RH in turn increases the entropy of the system,
increasing the interparticle interactions. At a lower
temperature, the emulsifier stabilizing the nano
particles avoids fusion of the particles due to its
microviscosity (film rigidity). However, at a higher
temperature, the microviscosity of the emulsifier is
reduced. This reduced microviscosity along with the
increased interparticle interactions could lead to
aggregation and gelation, a phenomenon not ob-
served when the formulation was stored at lower
temperatures.67
Histological analysis of the rabbit corneas treated
with the SLNs helps understand the toxicity profile of
the SLNs. In corneas treated with control (Figs. 4D,
4E, 4F), we observe structurally disturbed collagen
bonds in areas close to the Descemet membrane
invagination. However, considering the exclusivity of
this event, the damage to this cornea can be attributed
to mechanical stress during the enucleation and the
fixing of the cornea. For corneas treated with
placebo-SLNs (Figs. 4A, 4B, 4C), the stroma is
present as even layers with signs of edema ranging
from slight to none.68
Topical THC-VHS-SLNs produced a prolonged
and intense drop in the IOP in normotensive rabbits
in comparison to THC-VHS-TOC as well as THC-
Figure 9. Percent IOP change from baseline versus time profile for THC-VHS-SLN, THC-VHS-TOC, and THC-SLN and 2% w/v pilocarpine
and 0.25% w/v timolol maleate marketed formulations. A single drop (50 lL) was instilled. Data represent mean 6 SE.
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SLNs. THC-VHS-SLNs lowered the IOP of the
treated eye in comparison to the untreated eye and
maintained IOP below baseline until 360 minutes. In
comparison, rabbit eyes treated with THC-VHS-TOC
produced a significant drop in IOP in comparison to
the untreated eye at 30, 60, and 90 minutes only.
Comparing the P values for differences in the IOP for
treated and untreated eyes, the IOP drop produced by
THC-VHS-TOC was not as significant as THC-VHS-
SLN. SLNs, being colloidal carriers, have advantages
of better penetration, stability, drug loading, and
sustained release of the drug.69 The large surface area
provided by the nanoparticulate system increased the
contact area, ensuring close contact with the ocular
mucosa after instillation. Lipid-based nanoparticles
have an occlusive effect and form a depot in the cul de
sac, slowly releasing the drug over a prolonged
duration of time.70,71 The additives present in the
formulations, such as surfactants, also play a role in
permeation enhancement via fluidization of the lipid
bilayers of the ocular membranes.72
The THC-SLN-treated eyes showed a statistically
significant lower IOP in comparison to the untreated
eyes at the 135-minute time point only. Based on the
IOP data, THC-VHS was effectively delivered to the
target tissues within the first 30 minutes from both the
SLN and emulsion-based formulations, whereas the
parent molecule required about 2 hours to demon-
strate a pharmacodynamic response.
The pharmacokinetic data suggest that the SLN
formulations deliver an almost 60 times greater
concentration of THC-VHS in the IC in comparison
to the emulsion formulation. THC levels in the ocular
tissues from the THC-VHS-SLN formulations were
extremely low (below detection levels in most cases) in
comparison to that obtained from the THC-VHS-
TOC or THC-SLN formulations. However, the
duration of IOP drop observed with the THC-VHS-
SLNs was significantly more prolonged. A possible
explanation for this disconnect between the PK-PD
observations could be that the site of action might not
be the IC. It could also be possible that the prodrug
being more permeable could be distributing deeper
into the tissues better than THC (administered as such
or THC generated from THC-VHS). As a result, a
correlation between the prodrug concentration, rather
than THC concentration, and IOP-lowering effect are
observed. The lack of a pharmacodynamic response
even though the ocular tissues exhibited significant
THC concentrations (with the THC-VHS-TOC and
THC-SLN formulations) could be because of THC
forming a depot in the ocular tissues, rather than
penetrating and distributing across the ocular tissues
(e.g., IC). As a result, concentrations at the site of
action may be low even though the overall tissue
concentrations are high.22 The reason why THC-
VHS-TOC is not as effective as THC-VHS-SLN
could be because the emulsion formulation is not
protecting the prodrug from bioreversion (chemical or
enzymatic), as a result of which higher THC tissue
concentrations are observed from THC-VHS-TOC,
thus decreasing the concentration deeper in the
tissues. On the other hand, the SLN formulation
protects against bioreversion of THC-VHS to THC,
as evidenced by the lack of detectable THC concen-
trations from the THC-VHS-SLN formulations.
The overall tissue distribution profile indicates a
noncorneal route of absorption. With THC-VHS-
SLN, we observe 1466 6 514.50 ng/50 mg tissue of
THC-VHS in the IC at 90 minutes. The prodrug
concentrations dropped almost 20-fold at 360 min-
utes, which can be explained by elimination and slow
conversion into THC, which was also detected then.
We also observe THC-VHS partitioning into the RC,
from both THC-VHS-TOC and THC-VHS-SLN
formulations, which is important for the neuropro-
tective action. With THC-SLNs, however, we observe
THC levels in the IC at both sacrifice time points, but
THC fails to distribute itself across other tissues. The
preferential accumulation of THC in the IC could
indicate binding of THC to an IC-specific protein.
The IOP-lowering duration with THC-VHS-SLNs
lasted almost twice as long as the marketed formu-
lations 2.5% w/v pilocarpine or 0.2% w/v timolol
maleate. A combined effect of prodrug derivatization
and the dosage form can be attributed to this effect, as
the prodrug alone (in an emulsion formulation) or the
parent compound THC in an SLN formulation were
not effective. The molecule design facilitated easy
passage of the parent molecule across the ocular
tissues and the lipid-based nanocarrier system acted
as a long-acting depot, resulting in a formulation with
better PK-PD profile.
Conclusion
THC has been demonstrated to be effective in
glaucoma management, helping to lower IOP in
human subjects after smoking marijuana; however,
the molecule fails to manifest a similar effect when
dosed topically. This research explores molecular
bioengineering and formulation-based strategies to
improve the ocular bioavailability of THC, facilitat-
ing the molecule to translate into a dosage form
capable of demonstrating a desired IOP-lowering
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effect even on topical application. These studies
suggest that formulation development efforts along
with prodrug derivatization can effectively improve
the overall ocular bioavailability of THC. THC-VHS-
SLNs were successfully formulated and tested in a
normotensive rabbit model. Results suggested that
the prodrug THC-VHS has a better permeation
profile than THC due to its modified structure. SLNs
are efficient in the delivery of THC-VHS to the RC,
which is important from the point of view of
neuroprotection. THC-VHS-SLNs, on multiple dos-
ing, were able to achieve an intense IOP drop, with its
effect lasting for a longer duration than the marketed
solutions of 2.5% w/v pilocarpine HCl and 0.2% w/v
timolol maleate. Thus, THC-VHS represents a
potential new therapy option for the treatment and
management of glaucoma by virtue of its superiority
in lowering IOP when compared to antiholinergic and
beta blockers, as studied in this model. Further
analyses are needed to understand the impact of the
endocannabinoid-receptor system in the eye and its
relation to the THC-VHS mechanism of action as well
as the impact on the direct neuroprotective activity of
preserving RGCs by cannabinoids.
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